MRD
A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Enrollment
- 400 patients (estimated)
- Sponsors
- University of Rochester
- Tags
- Minimal Residual Disease (MRD)
- Trial Type
- Observational
- Last Update
- 4 weeks ago
- SparkCures ID
- 1498
- NCT Identifier
- NCT01311258
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.